Company Filing History:
3 out of 417 
2 out of 27 
1 out of 9 Years Active: 1986-2025
Title: Innovations of Hideyuki Watanabe
Introduction
Hideyuki Watanabe is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for cancer treatment. With a total of 4 patents, Watanabe's work focuses on innovative solutions to combat various forms of cancer.
Latest Patents
Watanabe's latest patents include a quinazoline compound designed to induce degradation of the G12D mutant KRAS protein. This compound serves as an active ingredient in pharmaceutical compositions aimed at treating pancreatic cancer. The research highlights the compound's excellent degradation-inducing action on the G12D mutant KRAS protein, making it a promising therapeutic agent for pancreatic cancer. Another notable patent is the pyridazinyl-thiazolecarboxamide compound, which is useful for treating cancers related to immune cell activation or those resistant to anti-PD-1/anti-PD-L1 antibody therapies. This compound exhibits a DGK ξ inhibitory effect, further establishing its potential as a therapeutic agent.
Career Highlights
Throughout his career, Watanabe has worked with notable companies such as Astellas Pharma GmbH and Kotobuki Pharmaceutical Co. Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovation and development.
Collaborations
Watanabe has collaborated with esteemed colleagues, including Yohei Seki and Keiichiro Okuyama. These partnerships have facilitated the advancement of his research and the successful development of his patented compounds.
Conclusion
Hideyuki Watanabe's innovative work in the pharmaceutical field demonstrates his commitment to advancing cancer treatment. His patents reflect a deep understanding of the complexities of cancer biology and the potential for new therapeutic strategies.